伴高危特征的高血压对隐源性卒中抗栓治疗效应的影响
该研究为ARCADIA随机临床试验的探索性分析,纳入945例近期隐源性卒中伴心房心脏病患者,比较阿哌沙班与阿司匹林对复发性缺血性卒中或系统性栓塞的影响。中位随访1.6年,67例发生主要结局;伴高危特征的高血压与抗栓治疗存在显著交互作用,无高危特征者阿哌沙班优于阿司匹林(HR 0.43,95%CI 0.22-0.85),而有高危特征者无显著差异(HR 1.68,95%CI 0.78-3.62)。
要点
- 伴高危特征的高血压可能改变隐源性卒中抗栓治疗的效应。
- 无高危特征者阿哌沙班较阿司匹林显著降低复发风险。
- 有高危特征者阿哌沙班与阿司匹林无显著差异。
核心结论
- 伴高危特征的高血压可能与隐源性卒中患者抗栓治疗效应的改变相关。
- 未被识别的高血压性动脉病所致卒中可能解释既往抗凝试验缺乏获益。
研究设计与样本
- ARCADIA随机临床试验的探索性分析,原试验于2018年2月至2023年2月在北美185个中心开展。
- 从1015例随机患者中纳入945例有高血压数据的近期隐源性卒中伴心房心脏病患者。
- 干预为阿哌沙班5 mg或2.5 mg每日两次 vs 阿司匹林81 mg每日一次。
主要发现
- 945例患者平均年龄68.0岁(SD 10.8),女性513例(54.3%)。
- 351例(37.1%)符合伴高危特征的高血压标准。
- 中位随访1.6年(IQR 0.7-3.0),67例发生复发性缺血性卒中或系统性栓塞。
- 无高危特征者阿哌沙班较阿司匹林HR 0.43(95%CI 0.22-0.85),年化率差-3.4%。
- 有高危特征者HR 1.68(95%CI 0.78-3.62),年化率差2.4%。
关键数值与推荐
- 伴高危特征的高血压定义为入组时收缩压≥160 mm Hg、超声心动图左心室肥厚或两者兼有。
- 主要结局为复发性缺血性卒中或系统性栓塞。
- 采用Cox比例风险模型评估治疗交互作用并估计亚组风险比。
临床怎么用
- 对隐源性卒中患者评估高血压高危特征(收缩压≥160 mm Hg或左心室肥厚)可能有助于识别抗凝获益人群。
- 无高危特征的高血压患者中阿哌沙班可能优于阿司匹林,有高危特征者抗凝未见显著获益。
局限性
- 本研究为探索性分析,结果需进一步验证。
- 排除了缺失血压和超声心动图数据的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiple trials have found no difference in secondary stroke prevention between anticoagulation and antiplatelet therapy after cryptogenic stroke. Due to limitations of current stroke mechanism classification, one possible explanation is the failure to exclude patients with hypertension-related cerebrovascular disease. OBJECTIVE: To determine whether hypertension with high-risk features is associated with treatment effect modification of anticoagulation vs antiplatelet therapy. DESIGN, SETTING, AND PARTICIPANTS: This exploratory analysis of the Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy (ARCADIA) randomized clinical trial was conducted between April and August 2025. The original trial was conducted from February 2018 to February 2023 at 185 sites in North America. From 1015 randomized patients with a recent cryptogenic stroke and atrial cardiopathy, 945 with available hypertension data were included in this analysis after exclusions for missing blood pressure and echocardiography data. INTERVENTIONS: Apixaban, 5 mg or 2.5 mg, twice daily vs aspirin, 81 mg, once daily. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent ischemic stroke or systemic embolism. Hypertension with high-risk features was defined as systolic blood pressure ≥160 mm Hg at enrollment, left ventricular hypertrophy on echocardiography, or both. Cox proportional hazards models evaluated treatment interaction with hypertension with high-risk features and estimated hazard ratios within hypertension with high-risk features subgroups. RESULTS: Among 945 patients (mean [SD] age, 68.0 [10.8] years; 513 [54.3%] female), 351 (37.1%) met criteria for hypertension with high-risk features. Over a median (IQR) follow-up of 1.6 (0.7-3.0) years within the analytic cohort, 67 patients experienced a recurrent ischemic stroke or systemic embolism. A significant interaction between hypertension with high-risk features and antithrombotic treatment was observed. In 594 patients without hypertension with high-risk features, apixaban was associated with lower risk compared to aspirin (hazard ratio [HR], 0.43; 95% CI, 0.22-0.85; annualized rate difference: -3.4%), whereas no significant association was observed in patients with hypertension with high-risk features (HR, 1.68; 95% CI, 0.78-3.62; annualized rate difference: 2.4%). CONCLUSIONS AND RELEVANCE: The findings in this study indicate that hypertension with high-risk features may be associated with modifications in the effect of antithrombotic treatment in patients with cryptogenic stroke. An unappreciated inclusion of strokes due to hypertensive arteriopathy may account for the lack of benefit with anticoagulation in prior trials of embolic stroke of undetermined source. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03192215.
引用
- Ridha M, Hailat R, Stanton R, et al. Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42008258. doi:10.1001/jamaneurol.2026.0855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。